2024 Asia Conference on Lung Cancer (ACLC) - Poster & ePosters-PP01.05

PP01.05 - Zhijuan Du

Pdf Summary

This multicenter retrospective study analyzes the clinical characteristics and survival outcomes of patients diagnosed with pulmonary sarcomatoid carcinoma (PSC), a highly rare and aggressive form of lung cancer. The investigation involved 81 PSC cases and 337 cases of lung adenocarcinoma (LUAD) as a reference group. Using a 1:1 propensity score matching for factors like age and cancer stage, 53 PSC and LUAD patients were directly compared.<br /><br />Results reveal that PSC patients generally experience worse progression-free survival (PFS) and overall survival (OS) rates compared to those with LUAD, with spindle cell carcinoma (SCC), a subtype of PSC, showing the poorest prognosis. The study also underscores the significant presence of KRAS and EGFR mutations in PSC patients, adding a layer of complexity to its treatability and necessitating specific targeted therapies.<br /><br />The study evaluates the impact of immune-oncology (IO) treatments on survival outcomes. Among PSC patients treated with IO, a notable improvement in OS was observed over those who did not receive IO therapies, suggesting that IO could offer meaningful survival benefits even in advanced PSC stages. This underscores the potential of immunotherapy as a promising treatment approach.<br /><br />In conclusion, this study provides valuable insights into PSC, emphasizing its rarity but severe prognosis compared to more common lung cancers like LUAD. The demonstrated efficacy of IO therapies in enhancing survival rates offers hope for more effective individualized treatment protocols for PSC patients and underlines the urgent need for ongoing research in this area to refine and optimize therapeutic strategies.

Keywords

pulmonary sarcomatoid carcinoma

lung cancer

survival outcomes

propensity score matching

progression-free survival

KRAS mutations

EGFR mutations

immunotherapy

spindle cell carcinoma

immune-oncology treatments